Interim Phase II data from Moderna and Merck’s personalized mRNA neoantigen vaccine combined with pembrolizumab showed a 49% reduction in melanoma recurrence and deaths in resectable high‑risk patients versus control arms, according to trial results released by study investigators. The randomized KEYNOTE combination highlights continued clinical momentum for mRNA‑based cancer immunotherapies. Separately, process teams at Sartorius and Johannes Gutenberg University reported a rapid pH denaturation step that reduces dsRNA impurities in mRNA manufacturing to under 0.1% while preserving mRNA integrity and boosting expression in cell assays. The method uses brief exposure to pH ≤3.5 to denature dsRNA prior to chromatography, potentially reducing reliance on low‑yield cellulose or organic solvent methods. Together, the clinical readout and purification advances illustrate parallel progress in mRNA pipeline and manufacturing technologies: efficacy signals strengthen translational investment while production innovations address critical impurities that affect potency and reactogenicity.